🔗 Share this article The Global Health Body Sounds Concern Over Critical Scarcity of Obesity Injections Fewer than one in 10 individuals eligible to benefit from obesity jabs such as Wegovy can access them, warns the global health agency as it releases its first guidance on the medications. Given in excess of 1,000,000,000 people worldwide now obese, it is calling for broader and more equitable access to these injectable treatments. Per forecasts, more than two billion are projected to be obese by 2030 unless action is taken. "Our latest guidance acknowledges that excess weight is a long-term condition that can be addressed with comprehensive and continuous care," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are major barriers to universal access to the jabs that can aid individuals in losing significant body mass, explains the body. Skinny Jab Scarcity Even in the present most favorable case, the manufacturing of GLP-1 therapies might only reach about 100 million people – under 10% of the global need, per the WHO. The guideline calls on countries and companies to expand availability, through measures including voluntary licensing. A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026. The Way Weight-Loss Injections Function The injections replicate a biological compound to delay gastric emptying, suppress the appetite and enhance satiety so people consume fewer calories. People typically begin shedding pounds in the initial weeks of starting on the regular doses. Studies suggests patients may regain a significant portion after a year of stopping the treatment, because their normal appetite resume. To be above a healthy weight increases your likelihood for developing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and specific cancers. Obesity affects people in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the WHO.
Fewer than one in 10 individuals eligible to benefit from obesity jabs such as Wegovy can access them, warns the global health agency as it releases its first guidance on the medications. Given in excess of 1,000,000,000 people worldwide now obese, it is calling for broader and more equitable access to these injectable treatments. Per forecasts, more than two billion are projected to be obese by 2030 unless action is taken. "Our latest guidance acknowledges that excess weight is a long-term condition that can be addressed with comprehensive and continuous care," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are major barriers to universal access to the jabs that can aid individuals in losing significant body mass, explains the body. Skinny Jab Scarcity Even in the present most favorable case, the manufacturing of GLP-1 therapies might only reach about 100 million people – under 10% of the global need, per the WHO. The guideline calls on countries and companies to expand availability, through measures including voluntary licensing. A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026. The Way Weight-Loss Injections Function The injections replicate a biological compound to delay gastric emptying, suppress the appetite and enhance satiety so people consume fewer calories. People typically begin shedding pounds in the initial weeks of starting on the regular doses. Studies suggests patients may regain a significant portion after a year of stopping the treatment, because their normal appetite resume. To be above a healthy weight increases your likelihood for developing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and specific cancers. Obesity affects people in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the WHO.